During the past decade, Hospital Pakar Sultanah Fatimah conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 2 clinical trials were completed, i.e. on average, 22.2% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 2 clinical trials were completed. i.e. 28.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hospital Pakar Sultanah Fatimah" #1 sponsor was "Boehringer Ingelheim" with 4 trials, followed by "Bayer" with 1 trials sponsored, "EMD Serono Research & Development Institute, Inc." with 1 trials sponsored, "Janssen Research & Development, LLC" with 1 trials sponsored and "Livzon Pharmaceutical Group Inc." with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hospital Pakar Sultanah Fatimah" #1 collaborator was "Canadian Institutes of Health Research (CIHR)" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator, "Medical Research Council Population Health Research Unit, CTSU, University of Oxford (academic lead)" with 1 trials as a collaborator and "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Hospital Pakar Sultanah Fatimah" are "Generalized Pustular Psoriasis" (3 trials), "Arthritis, Psoriatic" (1 trials), "COVID-19 Pandemic" (1 trials), "Chronic Kidney Disease" (1 trials) and "Endstage Renal Disease" (1 trials). Many other conditions were trialed in "Hospital Pakar Sultanah Fatimah" in a lesser frequency.

Most popular intervention types in "Hospital Pakar Sultanah Fatimah" are "Drug" (8 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "Spesolimab" (3 trials), "Blank Preparation of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)" (1 trials), "Empagliflozin" (1 trials) and "Finerenone (BAY94-8862)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Hospital Pakar Sultanah Fatimah" are 9 trials for "All" genders.

Currently, there are NaN active trials in "Hospital Pakar Sultanah Fatimah". undefined are not yet recruiting, 3 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Hospital Pakar Sultanah Fatimah, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Hospital Pakar Sultanah Fatimah, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".